References
- CraigJPNicholsKKAkpekEKTFOS DEWS II definition and classification reportOcul Surf201715327628328736335
- BaudouinCMessmerEMAragonaPRevisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunctionBr J Ophthalmol2016100330030626781133
- StevensonWChauhanSKDanaRDry eye disease: an immune-mediated ocular surface disorderArch Ophthalmol201213019010022232476
- BronAJde PaivaCSChauhanSKTFOS DEWS II pathophysiology reportOcul Surf201715343851028736340
- MessmerEMThe pathophysiology, diagnosis, and treatment of dry eye diseaseDtsch Arztebl Int20151125718125686388
- ChiaEMMitchellPRochtchinaELeeAJMarounRWangJJPrevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye StudyClin Exp Ophthalmol200331322923212786773
- SchaumbergDASullivanDABuringJEDanaMRPrevalence of dry eye syndrome among US womenAm J Ophthalmol2003136231832612888056
- StapletonFAlvesMBunyaVYTFOS DEWS II epidemiology reportOcul Surf201715333436528736337
- SternMESchaumburgCSPflugfelderSCDry eye as a mucosal autoimmune diseaseInt Rev Immunol2013321194123360156
- CavoneLMuzziMMencucciR18β-glycyrrhetic acid inhibits immune activation triggered by HMGB1, a pro-inflammatory protein found in the tear fluid during conjunctivitis and blepharitisOcul Immunol Inflamm201119318018521426233
- DupireGNicaiseCGangjiVSoyfooMSIncreased serum levels of high-mobility group box 1 (HMGB1) in primary Sjögren’s syndromeScand J Rheumatol201241212012322248244
- OppenheimJJYangDAlarmins: chemotactic activators of immune responsesCurr Opin Immunol200517435936515955682
- BianchiMEDAMPs, PAMPs and alarmins: all we need to know about dangerJ Leukoc Biol200781115
- MollicaLDe MarchisFSpitaleriAGlycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activitiesChem Biol200714443144117462578
- FuYZhouEWeiZGlycyrrhizin inhibits the inflammatory response in mouse mammary epithelial cells and a mouse mastitis modelFEBS J2014281112543255724698106
- FengXDingLQiuFPotential drug interactions associated with glycyrrhizin and glycyrrhetinic acidDrug Metab Rev201547222923825825801
- TanakaHHasegawaTMatsushitaMMiichiHHayashiSQuantitative evaluation of ocular anti-inflammatory drugs based on measurements of corneal temperature in rabbits: dexamethasone and glycyrrhizinOphthalmic Res19871942132203501091
- TakeiHBabaYHisatsuneAGlycyrrhizin inhibits interleukin-8 production and nuclear factor-kappaB activity in lung epithelial cells, but not through glucocorticoid receptorsJ Pharmacol Sci2008106346046818344608
- MencucciRFavuzzaEMenchiniUAssessment of the tolerability profile of an ophthalmic solution of 5% glycyrrhizin and copolymer PEG/PPG on healthy volunteers and evaluation of its efficacy in the treatment of moderate to severe blepharitisClin Ophthalmol201371403141023874081
- JonesLDownieLEKorbDTFOS DEWS II management and therapy reportOcul Surf201715357562828736343
- WozniakPASchmidlDBataAMEffect of different lubricant eye gels on tear film thickness as measured with ultrahigh-resolution optical coherence tomographyActa Ophthalmol2017954e307e31327989018
- SchmidlDSchmettererLWitkowskaKJTear film thickness after treatment with artificial tears in patients with moderate dry eye diseaseCornea201534442142625651494
- BronAJEvansVESmithJAGrading of corneal and conjunctival staining in the context of other dry eye testsCornea200322764065014508260
- van BijsterveldOPDiagnostic tests in the Sicca syndromeArch Ophthalmol196982110144183019